Gene therapy: the future of SCD treatment?

In this video, Crawford Strunk, MD, Cleveland Clinic, Cleveland, OH, speaks on the promising future of gene therapy to rectify abnormal hemoglobin S genes in patients with sickle cell disease (SCD) and outlines the types of gene therapy which are up for FDA approval. Although this is an exciting avenue for curative treatment, Dr Strunk highlights the importance of continued research into other treatment options for patients who are not eligible for gene therapy. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.